WO1992017446A3 - Acides acetiques de pyridazinone utilises comme agents inhibiteurs de l'aldose-reductase - Google Patents

Acides acetiques de pyridazinone utilises comme agents inhibiteurs de l'aldose-reductase Download PDF

Info

Publication number
WO1992017446A3
WO1992017446A3 PCT/US1992/001603 US9201603W WO9217446A3 WO 1992017446 A3 WO1992017446 A3 WO 1992017446A3 US 9201603 W US9201603 W US 9201603W WO 9217446 A3 WO9217446 A3 WO 9217446A3
Authority
WO
WIPO (PCT)
Prior art keywords
aldose reductase
phenyl
reductase inhibitors
acetic acids
oxadiazol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1992/001603
Other languages
English (en)
Other versions
WO1992017446A2 (fr
Inventor
Banavara L Mylari
William J Zembrowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Priority to AU17796/92A priority Critical patent/AU658887B2/en
Priority to FI934222A priority patent/FI934222L/fi
Priority to BR9205810A priority patent/BR9205810A/pt
Priority to CS923870A priority patent/CZ387092A3/cs
Publication of WO1992017446A2 publication Critical patent/WO1992017446A2/fr
Publication of WO1992017446A3 publication Critical patent/WO1992017446A3/fr
Priority to NO93933446A priority patent/NO933446L/no
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Composés présentant une activité d'inhibition de l'aldose-réductase et répondant à la formule (I), dans laquelle X représente CH2, CH2CH2, -CHCH3 ou (a); Y=O ou S; R1 représente un groupe phényle, benzothiazol-2-yle, benzoxazol-2-yle, benzofuran-2-yle, benzothiophèn-2-yle, thiazopyridin-2-yle, oxazolopyridin-2-yle, 3-phényl-1,2,4-oxadiazol-5-yle, et 5-phényl-1,2,4-oxadiazol-3-yle éventuellement substitué, lesdits groupes substitués étant substitués par au moins un et de préférence deux substituants sélectionnés indépendamment les uns des autres parmi fluor, chlore, brome, méthyle et trifluorométhyle; R2 et R3 sont sélectionnés, indépendamment l'un de l'autre, parmi hydrogène, fluor, chlore, brome, alkyle (C¿1-4?), méthylalkylthio (C1-4), alcoxy (C1-4) et trifluorométhyle, ou forment conjointement avec les atomes de carbone auxquels ils sont liés un groupe W, où W représente (b) ou (c), où p est 1 ou 2 et U?1 et U2¿ représentent indépendamment CH¿2?, O ou S à condition que U?1 et U2¿ ne représentent pas tous les deux O ou S; R4 représente hygrogène ou un groupe précurseur de médicament; ou leur sel pharmaceutiquement acceptable.
PCT/US1992/001603 1991-03-28 1992-03-09 Acides acetiques de pyridazinone utilises comme agents inhibiteurs de l'aldose-reductase Ceased WO1992017446A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU17796/92A AU658887B2 (en) 1991-03-28 1992-03-09 Pyridazinone acetic acids as aldose reductase inhibitors
FI934222A FI934222L (fi) 1991-03-28 1992-03-09 Pyridazinonaettiksyror
BR9205810A BR9205810A (pt) 1991-03-28 1992-03-09 Acidos piridazinona acéticos
CS923870A CZ387092A3 (en) 1991-03-28 1992-03-09 Pyridazinoacetic acids, their derivatives, process of their preparation and use
NO93933446A NO933446L (no) 1991-03-28 1993-09-27 Pyridazinon-eddiksyrer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67691991A 1991-03-28 1991-03-28
US676,919 1991-03-28

Publications (2)

Publication Number Publication Date
WO1992017446A2 WO1992017446A2 (fr) 1992-10-15
WO1992017446A3 true WO1992017446A3 (fr) 1992-11-26

Family

ID=24716565

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1992/001603 Ceased WO1992017446A2 (fr) 1991-03-28 1992-03-09 Acides acetiques de pyridazinone utilises comme agents inhibiteurs de l'aldose-reductase

Country Status (19)

Country Link
EP (1) EP0582643A1 (fr)
JP (1) JPH06500793A (fr)
CN (1) CN1065269A (fr)
AU (1) AU658887B2 (fr)
BR (1) BR9205810A (fr)
CA (1) CA2107104A1 (fr)
CZ (1) CZ387092A3 (fr)
DE (1) DE9290035U1 (fr)
FI (1) FI934222L (fr)
HU (1) HUT67836A (fr)
IE (1) IE920979A1 (fr)
IL (1) IL101325A0 (fr)
MX (1) MX9201414A (fr)
NZ (1) NZ242152A (fr)
PT (1) PT100301A (fr)
TW (1) TW207998B (fr)
WO (1) WO1992017446A2 (fr)
YU (1) YU30392A (fr)
ZA (1) ZA922238B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE297902T1 (de) 2001-02-28 2005-07-15 Pfizer Prod Inc Sulfonyl-pyridazinon-derivate zur verwendung als aldose-reduktase-inhibitoren
SE0100873D0 (sv) * 2001-03-13 2001-03-13 Astrazeneca Ab Method of treatment
EP1491541B1 (fr) 2001-03-30 2007-01-24 Pfizer Products Inc. Pyridazinones, inhibiteurs d'aldose reductase.
AU761191B2 (en) * 2001-05-24 2003-05-29 Pfizer Products Inc. Therapies for tissue damage resulting from ischemia
US7572910B2 (en) 2003-02-20 2009-08-11 Pfizer, Inc. Pyridazinone aldose reductase inhibitors
CN111617072B (zh) * 2019-02-27 2023-06-20 苏州凯祥生物科技有限公司 一种高尿酸血症药物组合物及用于治疗高尿酸血症的药物

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0295051A2 (fr) * 1987-06-09 1988-12-14 Pfizer Inc. Préparation d'acides oxophtalazinylacétiques ayant du benzothiazole ou d'autres groupes hétérocycliques comme chaînes latérales
FR2647676A1 (fr) * 1989-06-05 1990-12-07 Union Pharma Scient Appl Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0295051A2 (fr) * 1987-06-09 1988-12-14 Pfizer Inc. Préparation d'acides oxophtalazinylacétiques ayant du benzothiazole ou d'autres groupes hétérocycliques comme chaînes latérales
FR2647676A1 (fr) * 1989-06-05 1990-12-07 Union Pharma Scient Appl Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase

Also Published As

Publication number Publication date
NZ242152A (en) 1994-07-26
FI934222A0 (fi) 1993-09-27
IL101325A0 (en) 1992-11-15
WO1992017446A2 (fr) 1992-10-15
CA2107104A1 (fr) 1992-09-29
EP0582643A1 (fr) 1994-02-16
AU1779692A (en) 1992-11-02
MX9201414A (es) 1992-10-01
IE920979A1 (en) 1992-10-07
HUT67836A (en) 1995-05-29
FI934222A7 (fi) 1993-09-27
BR9205810A (pt) 1994-06-28
JPH06500793A (ja) 1994-01-27
CZ387092A3 (en) 1994-02-16
ZA922238B (en) 1993-09-27
CN1065269A (zh) 1992-10-14
DE9290035U1 (de) 1993-11-18
FI934222L (fi) 1993-09-27
TW207998B (fr) 1993-06-21
AU658887B2 (en) 1995-05-04
HU9302728D0 (en) 1993-12-28
YU30392A (sh) 1994-11-15
PT100301A (pt) 1993-06-30

Similar Documents

Publication Publication Date Title
IL104614A (en) 4-benzoylisoxazole derivatives and herbicidal compositions comprising them
CA2299355A1 (fr) Derives de l'acide aryloxyarylsulfonylamino hydroxamique
DK0771794T3 (da) Oxygenholdige heterocykliske forbindelser
YU49122B (sh) Supstituisana benzilaminopiperidinska jedinjenja
MX9804105A (es) Antagonistas de taquicininas a base de piperidonas.
AU4091389A (en) Antidepressant n-substituted nicotinamide compounds
IE811085L (en) Pyridoxine derivatives
CA2117413A1 (fr) Derives herbicides isoxazole-4-yl-methanone
YU18999A (sh) Supstituisani tricikli
YU12992A (sh) 2-amino-1,2,3,4,-tetrahidronaftaleni supstituisani u prstenu
AU8240391A (en) Ring-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes, 3-aminochromanes, and 3-aminothiochromanes
NO175254C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive derivater av N-sulfonylindolin
WO1992017446A3 (fr) Acides acetiques de pyridazinone utilises comme agents inhibiteurs de l'aldose-reductase
KR900018092A (ko) 만성 당뇨병의 합병증 치료용 피리도-피리다지논 아세트산
WO2001098248A3 (fr) Inhibiteurs d'integrase du vih
EA200201255A1 (ru) Ненуклеозидные ингибиторы обратной транскриптазы
IE45556L (en) 2-[n-(cycloalkylmethyl)-n-(phenyl)-amino]-2- imidazoline¹derivatives
YU52498A (sh) UPOTREBA 2-ARILBENZO (b) TIOFENA ZA DOBIJANJE LEKA
AU7733491A (en) Isochromane derivatives
MY104955A (en) Pyrroloquinoline and pyrrolophemothiazine carboxamides and related compounds.
EP0507637A3 (fr) Utilisation de carboxamides benzobicycliques pour la fabrication d'un médicament pour l'utilisation comme analgésique
CA2056814A1 (fr) Derives de benzoxazinone et de benzothiazinone possedant une activite cardiovasculaire
HUP0002075A2 (hu) Fungicid keverékek
DE69835966D1 (de) Medizinische anwendungen von phenylalkanolen und derivaten davon
JPS6429367A (en) 2-amino-5-hydroxy-4-pyrimidone

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU BR CA CS DE FI HU JP KR NO PL RU US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU BR CA CS DE FI HU JP KR NO PL RU US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE

CFP Corrected version of a pamphlet front page

Free format text: REVISED TITLE RECEIVED BY THE INTERNATIONAL BUREAU AFTER COMPLETION OF THE TECHNICAL PREPARATIONS FOR INTERNATIONAL PUBLICATION

WWE Wipo information: entry into national phase

Ref document number: PV1992-3870

Country of ref document: CZ

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
EX32 Extension under rule 32 effected after completion of technical preparation for international publication
LE32 Later election for international application filed prior to expiration of 19th month from priority date or according to rule 32.2 (b)
WWE Wipo information: entry into national phase

Ref document number: 1992910955

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2107104

Country of ref document: CA

Ref document number: 934222

Country of ref document: FI

ENP Entry into the national phase

Ref document number: 1993 122495

Country of ref document: US

Date of ref document: 19930928

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: PV1992-3870

Country of ref document: CZ

Ref document number: 1992910955

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: PV1992-3870

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1992910955

Country of ref document: EP